An Open-label, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
Latest Information Update: 22 May 2025
At a glance
- Drugs Trospium chloride/xanomeline (Primary) ; Xanomeline (Primary)
- Indications Psychiatric disorders
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 14 May 2025 Status changed from not yet recruiting to recruiting.
- 05 Mar 2025 New trial record